In 2009, heterodimeric RGD-BBN peptidic analogues, containing an RGD (cyclo(Arg-Gly-Asp-D-Tyr-Lys) and a BBN(Aca-BBN(7–14), Aca: 6-Aminocaproic Acid) moieties were designed for the dual targeting of GRPR and integrin αvβ3, a protein involved in cancer angiogenesis. Here, GRPR is linked to cancer.